<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03372447</url>
  </required_header>
  <id_info>
    <org_study_id>HE17-00023</org_study_id>
    <nct_id>NCT03372447</nct_id>
  </id_info>
  <brief_title>Megadose of Hydroxocobalamin for the Treatment of Pernicious Anemia</brief_title>
  <official_title>Megadose of Hydroxocobalamin (Vitamin B12) for the Treatment of Pernicious Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate the effectiveness of a single dose of a multivitamin complex for the treatment of
      megaloblastic anemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will administrate a single intramuscular dose of hydroxocobalamin
      10,000mcg, Thiamin 100mg, Pyridoxine 50mg.

      To assess response to treatment, a complete blood count (CBC) will be performed weekly during
      the first month of treatment, after the first month a CBC will be taken monthly for 6 months.

      Also to confirm the diagnosis and assess response the investigators will measure levels of
      methylmalonic acid, homocysteine, and hydroxocobalamin at the beginning of the study, 3 and 6
      months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematologic response</measure>
    <time_frame>2 month</time_frame>
    <description>Normalization of complete blood count (CBC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of hematologic response</measure>
    <time_frame>6 months</time_frame>
    <description>Duration of response (months) after the administration of megadose of hydroxocobalamin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure levels of hydroxocobalamin</measure>
    <time_frame>Basal, three and six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure levels of methylmalonic acid.</measure>
    <time_frame>Basal, three and six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure levels of homocysteine.</measure>
    <time_frame>Basal, three and six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate time to hematologic response</measure>
    <time_frame>1 month</time_frame>
    <description>Time to response after the administration of 10,000mcg hydroxocobalamin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Megaloblastic Anemia Nos</condition>
  <condition>Pernicious Anemia</condition>
  <arm_group>
    <arm_group_label>Megadose multivitamin complex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg</intervention_name>
    <description>Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.</description>
    <arm_group_label>Megadose multivitamin complex</arm_group_label>
    <other_name>Bedoyecta Tri</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age &gt;18, All sex Clinical suspicious of megaloblastic anemia ( cytopenias and macrocytosis
        (CBC), hypersegmented neutrophils and elevated lactate dehydrogenase) Patients must sign an
        informed consent indicating that they are aware of the investigational nature of this study
        -

        Exclusion Criteria:

        Administration of hydroxocobalamin in the three years before enrollment Patients with
        active, uncontrolled psychiatric disorders Severe neurologic deficit Known hematologic
        malignancy Known coagulation disorder that contraindicates intramuscular injection
        End-stage kidney disease (GFR &lt;15ml/min) Chronic liver disease (Child-Pugh B or C) Pregnant
        patients Known infection of Hepatitis B or C and HIV Diagnosis of myelodysplastic syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gómez Almaguer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Dr. José Eleuterio González</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Gómez Almaguer, MD</last_name>
    <phone>52 81 8348-8510</phone>
    <email>dgomezalmaguer@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>César O Pezina Cantú, MD</last_name>
    <phone>528115273932</phone>
    <email>cpezina@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose E Gonzalez UANL</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Gomez-Almaguer, MD</last_name>
      <phone>52 8183488510</phone>
      <email>dgomezalmaguer@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>César O Pezina-Cantú, MD</last_name>
      <phone>52 8115273932</phone>
      <email>cpezina@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Gomez-Almaguer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Sanz-Cuesta T, González-Escobar P, Riesgo-Fuertes R, Garrido-Elustondo S, del Cura-González I, Martín-Fernández J, Escortell-Mayor E, Rodríguez-Salvanés F, García-Solano M, González-González R, Martín-de la Sierra-San Agustín MÁ, Olmedo-Lucerón C, Sevillano Palmero ML, Mateo-Ruiz C, Medina-Bustillo B, Valdivia-Pérez A, García-de Blas-González F, Mariño-Suárez JE, Rodríguez-Barrientos R, Ariza-Cardiel G, Cabello-Ballesteros LM, Polentinos-Castro E, Rico-Blázquez M, Rodríguez-Monje MT, Soto-Díaz S, Martín-Iglesias S, Rodríguez-González R, Bretón-Lesmes I, Vicente-Herrero M, Sánchez-Díaz J, Gómez-Gascón T, Drake-Canela M, Asúnsolo-del Barco Á; OB12 Group. Oral versus intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency: a pragmatic, randomised, multicentre, non-inferiority clinical trial undertaken in the primary healthcare setting (Project OB12). BMC Public Health. 2012 May 31;12:394. doi: 10.1186/1471-2458-12-394.</citation>
    <PMID>22650964</PMID>
  </results_reference>
  <results_reference>
    <citation>Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013 May 23;368(21):2041-2. doi: 10.1056/NEJMc1304350.</citation>
    <PMID>23697526</PMID>
  </results_reference>
  <results_reference>
    <citation>Green R. Vitamin B(12) deficiency from the perspective of a practicing hematologist. Blood. 2017 May 11;129(19):2603-2611. doi: 10.1182/blood-2016-10-569186. Epub 2017 Mar 30. Review.</citation>
    <PMID>28360040</PMID>
  </results_reference>
  <results_reference>
    <citation>Sharabi A, Cohen E, Sulkes J, Garty M. Replacement therapy for vitamin B12 deficiency: comparison between the sublingual and oral route. Br J Clin Pharmacol. 2003 Dec;56(6):635-8.</citation>
    <PMID>14616423</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>David Gomez Almaguer</investigator_full_name>
    <investigator_title>Principal Investigator / Head of Hematology Department/MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Pernicious</mesh_term>
    <mesh_term>Anemia, Megaloblastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thiamine</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plans for a sharing plan pre-determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

